These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 991153)

  • 1. Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
    Lowitz BB
    Cancer Treat Rep; 1976 May; 60(5):623-4. PubMed ID: 991153
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chemotherapy in advanced cancer of the lung].
    Fleischer I; Wainstein R; Jovtis SL; Gibson AM; Barousse AP
    Medicina (B Aires); 1979; 39(4):472-6. PubMed ID: 545078
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of chemotherapy in the treatment of lung cancer.
    Selawry OS
    Semin Oncol; 1974 Sep; 1(3):259-72. PubMed ID: 4143488
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan.
    Bonadonna G; Tancini G; Bajetta E
    Cancer Chemother Rep 3; 1973 Mar; 4(2):231-7. PubMed ID: 4125741
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cytostatic therapy of tumors of the lung].
    De Marco F; Saviano G; Tenore G
    Arch Monaldi; 1974; 29(3-4):326-35. PubMed ID: 4463917
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of advanced bronchogenic carcinoma with adriamycin, 5-fluorouracil and methotrexate.
    Anderson G; Thomas G; Stewart-Jones J
    Br J Dis Chest; 1977 Jul; 71(3):179-82. PubMed ID: 302119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with methotrexate (NSC-740), adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and 5-fluorouracil (NSC19893) for adult solid tumors.
    Stephens RL; Hoogstraten B
    Cancer Chemother Rep; 1974; 58(6):943-5. PubMed ID: 4614901
    [No Abstract]   [Full Text] [Related]  

  • 8. Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
    Block NL; Camuzzi F; Stover B; Claflin A; Troner M; Politano VA
    Trans Am Assoc Genitourin Surg; 1978; 70():57-9. PubMed ID: 753023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin and polychemotherapy for treatment of lung cancer.
    Rohwedder JJ; Sagastume E
    Cancer Treat Rep; 1977 Oct; 61(7):1399-401. PubMed ID: 589603
    [No Abstract]   [Full Text] [Related]  

  • 10. Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
    Rak J; Kuśnierczyk H; Strzadała L; Kłosiewicz S; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):389-97. PubMed ID: 2639635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of individual sensitivity to chemotherapy of human pulmonary tumors transplanted to subrenal capsule of CBA mice].
    Skotinkova OI; Sergeeva NS; Moroz IA; Sviridova IK; Pelevina II
    Eksp Onkol; 1990; 12(4):71-3. PubMed ID: 2379492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
    Eagan RT; Hahn RG; Myers RP
    Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug therapy of pulmonary metastases of breast cancer].
    Voznyĭ EK; Meshcheriakova NG; Melent'eva EG; Al'tshuler IuB
    Sov Med; 1990; (5):110-4. PubMed ID: 2389192
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficiency and side effects of adriamycin-cyclophosphamide therapy compared to a triple combination of cyclophosphamide, methotrexate and 5-fluoro-uracil].
    Weymar P; Schulz KD; Noldus B; Schmidt-Rhode P
    Arch Gynecol; 1979 Jul; 228(1-4):445-6. PubMed ID: 485425
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
    Drago JR; Goldman LB; Maurer RE; Gershwin ME; Eckels DD
    Invest Urol; 1979 Nov; 17(3):203-6. PubMed ID: 500317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factors in the chemotherapy of bronchial cancers].
    Alberto P
    Schweiz Med Wochenschr; 1974 Feb; 104(8):268-71. PubMed ID: 4360755
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung.
    Eagan RT; Frytak S; Ingle JN; Creagan ET; Nichols WC; Kvols LK
    Cancer Treat Rep; 1980; 64(8-9):925-8. PubMed ID: 7192602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of advanced breast cancer. Results of a controlled trial comparing two three-drug regimens.
    Chauvergne J; Berlie J; Clavel B; Guerrin J; Gary-Bobo J; Brulé G; Klein T; Pommatau E; Carton M
    Eur J Cancer (1965); 1978 Sep; 14(9):911-7. PubMed ID: 361415
    [No Abstract]   [Full Text] [Related]  

  • 19. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
    Focan C
    Nouv Presse Med; 1975 Nov; 4(38):2709-12. PubMed ID: 1105421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.